RecruitingPhase 1NCT06819293

IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma

A Phase I, Open Label, Single Center Study Evaluating the Safety and Efficacy of IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma

Sponsor

Grit Biotechnology

Enrollment

12 participants

Start Date

Dec 6, 2024

Study Type

INTERVENTIONAL

Conditions

Adult Advanced Clear Renal Cell Carcinoma

Summary

This is an open label, single center, dose escalation, and dose extension IIT study aimed at evaluating the safety, efficacy, and pharmacokinetics of IB-T101 in adult patients with advanced clear renal cell carcinoma

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests an experimental treatment called IB-T101 — a type of cell therapy — for patients with advanced clear cell kidney cancer (clear cell renal cell carcinoma) that has not responded to previous treatments. **You may be eligible if...** - You are 18 or older - You have been diagnosed with advanced clear cell kidney cancer - You are in reasonably good health (ECOG 0 or 1) - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have significant brain or neurological problems (seizures, dementia, brain bleeding) - You are HIV positive or have a serious immune deficiency - You had a heart attack or unstable chest pain within the last 6 months - You have active autoimmune disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.